103-86-6

Basic information

• Product Name: Hydroxyamphetamine
• Synonyms: 4-(2-aminopropyl)phenol;p-Hydroxyamphetamine;2-(4-Hydroxyphenyl)-1-methylethylamine;.alpha.-Methyltyramine;1-p-Hydroxyphenyl-2-propylamine;2-Amino-1-(p-hydroxyphenyl)propane;4-Hydroxy-.alpha.-methylphenethylamine;Dl-p-(2-aminopropyl)phenol
• CAS NO: 103-86-6
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.20562
• EINECS: 203-152-8
• Mol File: 103-86-6.mol
• Article Data: 16

Chemical Properties

• Melting Point: 125-126 °C
• Boiling Point: 279.2 °C at 760 mmHg
• Flash Point: 122.7 °C
• Appearance: white like or light brown crystalline powder
• Density: 1.07 g/cm³
• PKA: 9.83±0.15(Predicted)
• CAS DataBase Reference: Hydroxyamphetamine(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxyamphetamine(103-86-6)
• EPA Substance Registry System: Hydroxyamphetamine(103-86-6)

Safety Data

• Hazardous Substances Data: 103-86-6(Hazardous Substances Data)

Usage

General Description

Hydroxyamphetamine is a synthetic derivative of amphetamine and is used primarily in ophthalmic medicine. When administered as eye drops, hydroxyamphetamine is employed to diagnose specific eye conditions.

Purification Methods

Crystallise the phenol from *benzene. The R-(-)-enantiomer crystallises from EtOH or *C6H6 with m 110.5-111.5o and []17 -52.0o (c 1, EtOH). The (±)-hydrochloride has m 171-172o (EtOH/Et2O), and the 2,4-dinitrophenylhydrazone has m 190-192o (EtOH). [Beilstein 13 I 251, 13 III 1709, 13 IV 1871.]

InChI:InChI=1S/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3

Upstream product

• 658-48-0 2-amino-3-(4-hydroxy-phenyl)-2-methyl-propionic acid 
• 60-15-1 2-amino-1-phenylpropane 
• 3240-42-4 p-Hydroxy-norephedrin-HCl 
• 56935-39-8 α-methyl-β-(p-methoxyphenyl)-propionyl chloride 
• 7176-39-8 2-(4-benzyloxy-phenyl)-1-methyl-ethylamine 
• 7176-38-7 1-(4-Benzyloxyphenyl)-2-nitro-1-propen 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 17354-63-1 4-(2-nitro-propenyl)-anisole 
• 123-11-5 4-methoxy-benzaldehyde 
• 37629-51-9 1-methoxy-4-((E)-2-nitroprop-1-enyl)benzene 
• 39755-38-9 3-(4'-methoxyphenyl)-2-methyl-propanamide 
• 770-39-8 4-methoxyphenylacetone 
• 27566-05-8 4-(2-(benzylamino)propyl)phenol 
• 57736-33-1 (+/-)-4-(2-amino-propyl)-aniline 

Downstream Products

• 103153-58-8 4-[2-(1-methyl-2-phenyl-ethylamino)-propyl]-phenol 
• 60677-79-4 (2,6-Dichloro-4-{1-hydroxy-2-[2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenyl)-carbamic acid ethyl ester 
• 27566-05-8 4-(2-(benzylamino)propyl)phenol 
• 1351781-81-1 C₁₂H₁₇NO₃ 
• 1518-89-4 (-)-Hydroxyamphetamine 
• 1693-66-9 (+)-Hydroxyamphetamine 
• 62401-66-5 p-Hydroxy-fenetyllin 
• 95939-49-4 4-[2-(2-Hydroxy-2-naphthalen-2-yl-ethylamino)-propyl]-phenol 
• 370-14-9 pholedrine 
• 1241224-85-0 C₁₉H₂₅N₃O₂ 
• 1241565-96-7 C₁₈H₃₀N₂O₂ 
• 1281135-71-4 1-[2-(4-hydroxy-phenyl)-1-methyl-ethyl]-3-(2-thiophen-2-yl-ethyl)-urea 
• 59481-71-9 tert-butyl N-[2-(4-hydroxyphenyl)-1-methyl-ethyl]carbamate 
• 99-96-7 4-hydroxy-benzoic acid 

Relevant articles and documents

-

-

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

MOF-derived cobalt nanoparticles catalyze a general synthesis of amines

The development of base metal catalysts for the synthesis of pharmaceutically relevant compounds remains an important goal of chemical research. Here, we report that cobalt nanoparticles encapsulated by a graphitic shell are broadly effective reductive amination catalysts. Their convenient and practical preparation entailed template assembly of cobaltdiamine- dicarboxylic acid metal organic frameworks on carbon and subsequent pyrolysis under inert atmosphere.The resulting stable and reusable catalysts were active for synthesis of primary, secondary, tertiary, and N-methylamines (more than 140 examples).The reaction couples easily accessible carbonyl compounds (aldehydes and ketones) with ammonia, amines, or nitro compounds, and molecular hydrogen under industrially viable and scalable conditions, offering cost-effective access to numerous amines, amino acid derivatives, and more complex drug targets.

AZETIDINE DERIVATIVES

Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.